Last reviewed · How we verify
NCT05828303
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Phase 1 trial testing TPX-0005 in Advanced Solid Tumor. Withdrawn.
31 July 2025
Quick facts
| Lead sponsor | Turning Point Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 15 November 2024 |
| Primary completion | 31 July 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 33 locations across France, Italy, Australia, Spain, United States, Brazil |
Drugs / interventions tested
- TPX-0005 — full drug profile →
- Metformin Hydrochloride — full drug profile →
- Digoxin (digoxin) — full drug profile →
- Rosuvastatin Calcium — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
- Metastatic Solid Tumor — all drugs for Metastatic Solid Tumor →
Sponsor
Turning Point Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumor or Metastatic Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Repurposing Cardiac Glycosides to Potentiate CD47 Blockade through Calreticulin-mediated Phagocytic Effects for Lung Cancer Treatment.
Ye ZH, Yu WB, Huang MY, Chen YY, et al · · 2025 · cited 2× · PMID 40985476 · DOI 10.1002/advs.202508245
Verify or expand the search:
- PubMed search for NCT05828303
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TPX-0005
Trials testing the same drug.
- NCT05071183 — A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant S · Phase 1, PHASE2 · terminated
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other Turning Point Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05828277 — A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer P · Phase 1 · withdrawn
- NCT05001516 — Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors · Phase 1 · completed
- NCT05071183 — A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant S · Phase 1, PHASE2 · terminated
- NCT04849273 — A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC · Phase 1 · terminated
- NCT04094610 — A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05828303 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Turning Point Therapeutics, Inc.
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05828303.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing